Smith Thornton Advisors’s AbbVie ABBV Stock Holding History

Smith Thornton Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	+852	New	+$183K	0.09%	131

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Smith Thornton Advisors's ABBV Position: Q2 2026 in Review

Smith Thornton Advisors opened a new position in AbbVie (ABBV) in Q2 2026: 852 shares worth $211K. The stake represents 0.09% of the portfolio and ranks #131 among its holdings.

1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Smith Thornton Advisors held 852 shares of AbbVie worth $211K as of Q2 2026.
AbbVie was a new Smith Thornton Advisors position in Q2 2026.
AbbVie made up 0.09% of Smith Thornton Advisors's portfolio in Q2 2026, its #131 holding.
1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Smith Thornton Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.